The University of Salamanca's Cytometry Service (NUCLEUS) and the biomedical company Atrys Health have become the first two bodies accredited under the ISO 15189 standard for EuroFlow Consortium panel analyses. It is a scientific Consortium whose objective is developing strategies and tools for standardising protocols and rapid, accurate approximations by flow cytometry for diagnosing and classifying malignant hematologic diseases, as well as assessing the applied treatment's effectiveness. 

In particular, the University of Salamanca's Cytometry Service (NUCLEUS) has been accredited for studies to detect Minimal Residual Disease by Next Generation Flow Cytometry in the bone marrow of patients with multiple myeloma after treatment. This analysis uses a highly sensitive methodology that detects small numbers of malignant cells in bone marrow persisting after treatment which are undetected by conventional methodology. This detection enables a highly efficient assessment of the response to therapy in patients with multiple myeloma and to predict its further evolution, constituting the basis of therapeutic decision-making in an increasing number of clinical trials.

Atrys Health has obtained ENAC's accreditation to carry out analysis aimed at diagnosing and monitoring panel plasma cell dyscrasias (PCD Euroflow). The accredited flow cytometry study allows normal and abnormal plasma cells to be distinguished contributing to the disease's diagnosis and allow its evolution to be monitored.